AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18481704 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education by nurses
Number of subjects: 4
Study 17032157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy in addition to treatment as usual
Number of subjects: 106
Study 17032157 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 106
Study 12743445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg
Number of subjects: 53
Study 12743445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10669153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy for 4 weeks
Number of subjects: 20
Study 10669153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10669153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 20
Study 9322469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance with 20 mL bupivacaine 0.5%
Number of subjects: 40
Study 9322469 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator (NS) with 20 mL bupivacaine 0.5%
Number of subjects: 40
Study 8493504 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam containing gamma‐2
Number of subjects: 20
Study 8493504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimaval (after challenge)
Number of subjects: 20
Study 8493504 — intervention group
Group type: COMPARATOR
Intervention: Amalgam free of gamma‐2
Number of subjects: 20
Study 3517650 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 70
Study 3517650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30612134 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 400
Study 30612134 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Sodium (75 mg)
Number of subjects: 400
Study 28580504 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Cognitive-Behavioral Therapy (ECBT)
Number of subjects: 92
Study 28580504 — intervention group
Group type: COMPARATOR
Intervention: Traditional Cognitive-Behavioral Therapy (CBT)
Number of subjects: 92
Study 26322555 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (∼ 5 mg · kg(‐1) body weight)
Number of subjects: 13
Study 26322555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24506989 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Number of subjects: 47
Study 22913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Late course accelerated hyperfractionated irradiation (LCAF)
Number of subjects: 111
Study 22913676 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAF with concurrent chemotherapy (LCAF + CT)
Number of subjects: 111
Study 22913676 — intervention group
Group type: COMPARATOR
Intervention: Control group (LCAF)
Number of subjects: 111
Study 22913676 — intervention group
Group type: COMPARATOR
Intervention: Control group (LCAF + CT)
Number of subjects: 111
Study 22913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group of patients
Number of subjects: 111
Study 22913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients (≥ 70 years)
Number of subjects: 111
Study 22913676 — intervention group
Group type: EXPERIMENTAL
Intervention: Living patients
Number of subjects: 111
Study 19969511 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radio-chemotherapy (RCT)
Number of subjects: 21
Study 17391930 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 5 mg for 6 weeks then donepezil 10 mg for six weeks
Number of subjects: 13
Study 17391930 — intervention group
Group type: COMPARATOR
Intervention: placebo donepezil for 12 weeks
Number of subjects: 13
Study 15359055 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice nursing support (telephone calls from an APN twice in the first week and weekly for 4 weeks)
Number of subjects: 200
Study 15359055 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 11260420 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous pressure (VP) monitoring
Number of subjects: 125
Study 11260420 — intervention group
Group type: EXPERIMENTAL
Intervention: Access flow (Qa) monitoring
Number of subjects: 125
Study 11260420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VP and Qa monitoring
Number of subjects: 125
Study 11260420 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 9884779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive precoated brackets (APC)
Number of subjects: 40
Study 9884779 — intervention group
Group type: COMPARATOR
Intervention: Straight‐Wire brackets with Transbond XT adhesive
Number of subjects: 40
Study 9884779 — intervention group
Group type: COMPARATOR
Intervention: Dyna‐Lock brackets with Right‐On adhesive
Number of subjects: 40
Study 9884779 — intervention group
Group type: EXPERIMENTAL
Intervention: Right‐On adhesive
Number of subjects: 40
Study 9884779 — intervention group
Group type: EXPERIMENTAL
Intervention: APC or Transbond adhesive
Number of subjects: 40
Study 8004731 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake intubation
Number of subjects: 13
Study 8004731 — intervention group
Group type: COMPARATOR
Intervention: Intubation following induction of anaesthesia with thiopentone 5 mg.kg‐1 and succinylcholine 2 mg.kg‐1
Number of subjects: 13
Study 2537830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine (C) against yellow fever and measles
Number of subjects: 219
Study 2537830 — intervention group
Group type: COMPARATOR
Intervention: Yellow fever vaccine only (A)
Number of subjects: 219
Study 2537830 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccine only (B)
Number of subjects: 219
Study 15231512 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (D2E7, adalimumab, Humira)
Number of subjects: 46
Study 15231512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31907054 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations
Number of subjects: 5
Study 31907054 — intervention group
Group type: COMPARATOR
Intervention: ICS treatment
Number of subjects: 5
Study 31907054 — intervention group
Group type: COMPARATOR
Intervention: Control arms (ICS, LABA, and/or placebo)
Number of subjects: 5
Study 30828762 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with diuretics and vasodilators
Number of subjects: 0
Study 30828762 — intervention group
Group type: COMPARATOR
Intervention: Novel treatments under development
Number of subjects: 0
Study 27312250 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes (score increase from 0-1 to 2-4)
Number of subjects: 6886
Study 27312250 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment in lifestyle score (each point increase)
Number of subjects: 6886
Study 27312250 — intervention group
Group type: EXPERIMENTAL
Intervention: One-point increase in lifestyle score from 2001 to 2004
Number of subjects: 6886
Study 25254357 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding events (PLATO definition)
Number of subjects: 18624
Study 25254357 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous bleeding
Number of subjects: 18624
Study 25254357 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-related bleeding
Number of subjects: 18624
Study 23751132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 12 weeks
Number of subjects: 30
Study 23751132 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 30
Study 21534246 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood temperature- and blood volume-control phase (CTL)
Number of subjects: 26
Study 21534246 — intervention group
Group type: COMPARATOR
Intervention: Standard phase (STD)
Number of subjects: 26
Study 19881973 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin 200 U/day + physical therapy (n = 23)
Number of subjects: 45
Study 19881973 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1,500 mg/day + physical therapy (n = 22)
Number of subjects: 45
Study 16891222 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nicotinamide (1.2 g/m2)
Number of subjects: 40
Study 16891222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15574071 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week interval-training program consisting of 2 specific 30-minute sessions per week of short high-intensity, intermittent-running aerobic exercises at velocities ranging from 100-130% of maximal aerobic speed
Number of subjects: 100
Study 15574071 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100
Study 11275164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg extended-release oxybutynin
Number of subjects: 382
Study 11275164 — intervention group
Group type: COMPARATOR
Intervention: 4 mg tolterodine (2 mg twice a day)
Number of subjects: 382
Study 11275164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms combined
Number of subjects: 382
Study 9223394 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bezafibrate
Number of subjects: 73
Study 9223394 — intervention group
Group type: COMPARATOR
Intervention: 10 mg simvastatin
Number of subjects: 73
Study 8477565 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg perindopril once daily
Number of subjects: 289
Study 8477565 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg perindopril twice daily
Number of subjects: 289
Study 8477565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 3673751 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring (CM)
Number of subjects: 296
Study 3673751 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 296
Study 31484277 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green near-infrared fluorescence imaging for extrahepatic cholangiography
Number of subjects: 48
Study 31484277 — intervention group
Group type: COMPARATOR
Intervention: Conventional X-ray cholangiopancreatography
Number of subjects: 48
Study 28430684 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (1.5 mg/kg)
Number of subjects: 200
Study 28430684 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study 25922454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip resurfacing
Number of subjects: 80
Study 25922454 — intervention group
Group type: COMPARATOR
Intervention: Cementless total hip arthroplasty
Number of subjects: 80
Study 23905378 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen quhan zhiwang decoction (BQZD) combined with methotrexate (MTX) 10 mg/week
Number of subjects: 240
Study 23905378 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 10 mg/week alone
Number of subjects: 240
Study 21448208 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (cord clamped at 35.2±10.1 s)
Number of subjects: 33
Study 21448208 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (cord clamped at 7.9±5.2 s)
Number of subjects: 33
Study 21448208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DCC and immediate cord clamping)
Number of subjects: 33
Study 19304088 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof MA60AC (Group 1)
Number of subjects: 59
Study 19304088 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT (Group 2)
Number of subjects: 59
Study 19304088 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT (Group 3)
Number of subjects: 59
Study 19304088 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 59
Study 16979636 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXO3A mutations (2/90; 2.2%)
Number of subjects: 90
Study 16979636 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXO1A mutations (1/90; 1.1%)
Number of subjects: 90
Study 15570766 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump conventional coronary artery surgery (150 patients)
Number of subjects: 300
Study 15570766 — intervention group
Group type: COMPARATOR
Intervention: Off-pump surgery (150 patients)
Number of subjects: 300
Study 15570766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB) inclusive of cardioplegic arrest
Number of subjects: 300
Study 10855632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (once-daily, subcutaneous)
Number of subjects: 157
Study 10855632 — intervention group
Group type: COMPARATOR
Intervention: Standard, continuous, adjusted-dose intravenous heparin
Number of subjects: 157
Study 9115057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fenoldopam (titrated up to 0.5 microgram/kg/min)
Number of subjects: 0
Study 9115057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9115057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fenoldopam
Number of subjects: 0
Study 8327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Forane (inhalation anesthetic)
Number of subjects: 0
Study 8327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (intravenous anesthetic)
Number of subjects: 0
Study 8327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Forane (inhalation anesthetic) at higher concentration
Number of subjects: 0
Study 8327167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthetic
Number of subjects: 0
Study 3544181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 47
Study 3544181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29858411 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health SMS reminders for ADA guidelines for 5 months
Number of subjects: 62
Study 29858411 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 62
Study 29858411 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health SMS reminders for ADA guidelines
Number of subjects: 62
Study 27488081 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice per day
Number of subjects: 102
Study 27488081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 24237751 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 10% solution once daily for 2 months
Number of subjects: 93
Study 24237751 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 4% solution once daily for 2 months
Number of subjects: 93
Study 22373561 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic image realignment mechanism activated mid-task
Number of subjects: 24
Study 22373561 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic image perfectly aligned with the actual task space (0° image orientation)
Number of subjects: 24
Study 22373561 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic image misaligned (various degrees of deviation from 0°)
Number of subjects: 24
Study 22373561 — intervention group
Group type: EXPERIMENTAL
Intervention: Various image orientations (8 total)
Number of subjects: 24
Study 22750263 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clonazepam
Number of subjects: 66
Study 22750263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18597830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg once daily titrated to 100 mg once daily)
Number of subjects: 369
Study 18597830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 369
Study 18597830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 16093466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion of tympanostomy tubes
Number of subjects: 429
Study 16093466 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of tympanostomy tubes
Number of subjects: 429
Study 11929471 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical nephrectomy via a transperitoneal approach
Number of subjects: 0
Study 11929471 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal (translumbar) approach
Number of subjects: 0
Study 11929471 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for non-disseminated disease
Number of subjects: 0
Study 11929471 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy and combined treatments
Number of subjects: 0
Study 12073205 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB initiated at F(I)O(2) of 1.0 (Group II, n = 7)
Number of subjects: 24
Study 12073205 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB initiated at F(I)O(2) of 0.21 (Group III, n = 7)
Number of subjects: 24
Study 12073205 — intervention group
Group type: COMPARATOR
Intervention: CPB initiated at F(I)O(2) of 1.0 (Group I, n = 10)
Number of subjects: 24
Study 9673439 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral D‐fenfluramine
Number of subjects: 7
Study 9673439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9673439 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐fenfluramine
Number of subjects: 7
Study 9673439 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐fenfluramine
Number of subjects: 7
Study 8020648 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer duration of 0.5 sec
Number of subjects: 60
Study 8020648 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer duration of 1.5 sec
Number of subjects: 60
Study 8020648 — intervention group
Group type: COMPARATOR
Intervention: Reinforcer duration of 4.0 sec
Number of subjects: 60
Study 2500718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enoxacin 400 mg
Number of subjects: 57
Study 2500718 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ceftriaxone 250 mg
Number of subjects: 57
Study 31373430 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach injection of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine
Number of subjects: 80
Study 31373430 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach injection of 40 mg/ml triamcinolone acetonide (Kenalog) and 4 ml 1% lignocaine
Number of subjects: 80
Study 31373430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 28701593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2 μg/kg/min following anesthesia induction till the end of the surgery
Number of subjects: 60
Study 28701593 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (no intervention)
Number of subjects: 60
Study 28701593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no renal dysfunction)
Number of subjects: 60
Study 25716463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 4832
Study 25716463 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4832
Study 22974973 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 1200 mg catechins, 240 mg caffeine/day for 7 days
Number of subjects: 27
Study 22974973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 27
Study 21375794 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 51
Study 21375794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg)
Number of subjects: 51
Study 21375794 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg) + Hydrocortisone (30 mg)
Number of subjects: 51
Study 21375794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19454560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 65 (mean perfusion pressure 60‐69.9 mmHg, n=68)
Number of subjects: 179
Study 19454560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 55 (mean perfusion pressure lower than 60 mmHg, n=59)
Number of subjects: 179
Study 19454560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 75 (mean perfusion pressure 70 mmHg and higher, n=52)
Number of subjects: 179
Study 19454560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group with ARF (n=19)
Number of subjects: 179
Study 19454560 — intervention group
Group type: COMPARATOR
Intervention: Group without ARF (n=160)
Number of subjects: 179
Study 19454560 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, valve replacement/reconstruction surgery, combined valve and CABG surgery, duration of CPB, duration of aortic cross‐clamp
Number of subjects: 179
Study 16998292 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVKA-II
Number of subjects: 227
Study 16998292 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVKA-II + AFP
Number of subjects: 227
Study 12664221 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 20
Study 12664221 — intervention group
Group type: COMPARATOR
Intervention: Proportional Assist Ventilation (PAV) 80
Number of subjects: 20
Study 12664221 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) 50
Number of subjects: 20
Study 11149433 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (n = 20)
Number of subjects: 52
Study 11149433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 22)
Number of subjects: 52
Study 11149433 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 10)
Number of subjects: 52
Study 9194006 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation before the scan
Number of subjects: 139
Study 9194006 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation before and during the scan
Number of subjects: 139
Study 9194006 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 139
Study 1288905 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 20
Study 1288905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG)
Number of subjects: 20
Study 31927671 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Korean Diet (BKD)
Number of subjects: 61
Study 31927671 — intervention group
Group type: COMPARATOR
Intervention: Typical American Diet (TAD)
Number of subjects: 61
Study 31927671 — intervention group
Group type: COMPARATOR
Intervention: 2010 Dietary Guidelines for Americans (2010DGA)
Number of subjects: 61